Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06450197 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
A Phase 2 study of Moderate to Severe Crohn's Disease, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT06450197 is a Phase 2 study of Moderate to Severe Crohn's Disease that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 120 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT06450197, a Phase 2 study of Moderate to Severe Crohn's Disease, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD7798
Study Locations (20)
Texas
- Research Site - Dallas
- Research Site - Garland
- Research Site - Mansfield
- Research Site - San Antonio
California
- Research Site - Escondido
- Research Site - La Jolla
- Research Site - Victorville
North Carolina
- Research Site - Asheville
- Research Site - Charlotte
- Research Site - Winston-Salem
Florida
- Research Site - Orlando
- Research Site - Tampa
Missouri
- Research Site - Liberty
- Research Site - St Louis
Arizona
- Research Site - Phoenix
Connecticut
- Research Site - Hamden
Idaho
- Research Site - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2027-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06450197
The ClinicalTrials.gov registry entry for NCT06450197 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06450197 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06450197 about?
NCT06450197 is a clinical study titled "Phase IIa Study Evaluating AZD7798 in Crohn's Disease". This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
What is the current status of trial NCT06450197?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-08-28. Estimated completion is 2027-05-14.
What conditions does trial NCT06450197 study?
This clinical trial studies the following conditions: Moderate to Severe Crohn's Disease.
What interventions are being tested in trial NCT06450197?
The interventions under investigation include: Placebo (OTHER), AZD7798 (DRUG).
Who is sponsoring clinical trial NCT06450197?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06450197 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.